我們已在上線! 進一步了解
PODD圖示

Insulet

141.10 USD
+2.33
1.68%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
140.96
-0.14
0.1%
1天
1.68%
5天
4.67%
1個月
0.36%
3個月
-14.19%
6個月
-29.96%
今年迄今
-50.13%
1年
-55.39%
5年
-51.66%
10年
258.67%
 

關於: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

員工: 5,400

新聞

正面
中性
負面
市場情緒 3個月
正面 5.8%
中性 92.3%
負面 1.9%
正面
Zacks Investment Research
15 小時前
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Insulet (PODD) is a Strong Growth Stock
中性
Business Wire
4 天前
Insulet Announces Omnipod Discover Now Available in U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover turns critical diabetes data into clear visualizations and personalized insights, giving people with diabetes and their HCPs a shared understanding of.
Insulet Announces Omnipod Discover Now Available in U.S.
中性
Business Wire
15 天前
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the.
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
正面
Zacks Investment Research
21 天前
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
正面
MarketBeat
21 天前
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet NASDAQ: PODD Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
中性
Seeking Alpha
22 天前
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
中性
Business Wire
28 天前
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About.
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
中性
Seeking Alpha
上個月
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
正面
Zacks Investment Research
上個月
Here's Why Insulet (PODD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Insulet (PODD) is a Strong Growth Stock
正面
Zacks Investment Research
上個月
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
價格圖表採用Lightweight Charts™實作